Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.70 -0.29 (2.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.99 | 52 Week High | $9.23 | |||
| Open | $9.84 | 52 Week Low | $1.16 | |||
| Day High | $9.93 | P/E | N/A | |||
| Day Low | $9.62 | EPS | $-0.30 | |||
| Volume | 4,418,344 | |||||
| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.70 -0.29 (2.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.99 | 52 Week High | $9.23 | |||
| Open | $9.84 | 52 Week Low | $1.16 | |||
| Day High | $9.93 | P/E | N/A | |||
| Day Low | $9.62 | EPS | $-0.30 | |||
| Volume | 4,418,344 | |||||
